Advertisement

Related Videos

Opening Session Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Feb
03
Today In Oncology
Deep Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
Head and Neck Cancer How Does Genetic Ancestry Impact Tumor Genomics
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo